Dorsal raphe nucleus enkephalin peptide modulates behavioral preference.
Enkephalin peptides in the brain’s dorsal raphe nucleus (DRN) just got a spotlight moment. Researchers at Washington University used CRISPR to knock down these endogenous opioids in mice. The result: major shifts in motivation and behavioral preference. This isn’t just another “peptide does something in the brain” study — it’s a clear signal that DRN enkephalins play a unique role in how animals respond to pain, rewards, and social cues.
Neuropsychopharmacology
by Braden K, Trinagel A, Acevedo E et al.
“Dorsal raphe nucleus enkephalin peptide modulates behavioral preference. Braden K(1), Trinagel A(2), Acevedo E(2), Massó-Quiñones LN(3), Bernstein AE(4), Arguello M(2), Evans-Strong A(4), Dunn SS(4), Castro DC(5). Author information: (1)Biophotonics Research Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO, USA. bradenk@wustl.edu. (2)College of Arts and Sciences, Washington University School of Medicine, Saint Louis, MO, USA. (3)Neuroscience Postbaccalaureate Research Education Program (Neuroprep), Washington University School of Medicine, Saint Louis, MO, USA. (4)Division of Biology and Biomedical Sciences, Neuroscience Program, Washington University School of Medicine, Saint Louis, MO, USA. (5)Biophotonics Research Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO, USA. The endogenous opioid system is a powerful modulator of motivation and affect. The dorsal raphe nucleus (DRN) in the midbrain has been established as an important site of opioid action and is an integral hub in behavioral modulation. To investigate the functional significance of DRN opioid signaling in aversive and appetitive behaviors we disrupted preproenkephalin (Penk) in DRN using CRISPR-Cas9 technology in Penk-Cre mice. We found that CRISPR mediated knockdown of enkephalin peptide in the DRN (DRNPenk) enhanced inflammation-induced mechanical sensitivity and odor avoidance. Additionally, loss of DRNPenk diminished sucrose preference and engagement with a novel social stimulus. To further characterize the opioid system within the DRN, we performed Hiplex in situ hybridization of 12 genes in the same tissue. This revealed that DRNPenk is largely separate from DRN serotonin cells and is instead distributed on glutamatergic and GABAergic cells. However, subtype-specific knockdown of DRNPenk from glutamatergic and GABAergic cells was insufficient to replicate the behavioral effects of general DRNPenk knockdown. This suggests that these neurons represent a novel population that mediate motivated behaviors distinctly from canonical DRN mechanisms. © 2026. The Author(s). Conflict of interest statement: Competing interests: The authors declare no competing interests.”
Here’s what stood out:
Knocking down enkephalin in the DRN ramped up pain sensitivity and made mice avoid odors they didn’t like.
The same mice lost interest in sugar water (a classic reward test) and spent less time with new social partners.
When researchers zoomed in on which cells were affected, they found DRN enkephalin isn’t tied to the serotonin cells most people focus on, but instead shows up on glutamatergic and GABAergic neurons.
Targeting only those subtypes didn’t recreate the full behavioral change — pointing to a more complex, previously overlooked population of DRN neurons.
Key takeaway: enkephalin peptides in the DRN are doing something special that standard neurotransmitter pathways can’t explain.
If you’re tracking opioid peptides, behavioral neuroscience, or CRISPR-based circuit mapping, this paper is a must-read. The findings open a new door for how peptide signaling shapes motivation and affect — and why classic models might be missing key players.
Curious about where this kind of research is heading? Check out the peptide research index for more studies pushing the boundaries of neuropeptide biology. Peptide research is just getting started, and the DRN is now firmly on the map.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.